Johnson & Johnson

NYSE:JNJ  
161.28
+1.17 (+0.73%)
4:37:52 PM EDT: $161.21 -0.07 (-0.04%)
Products

Janssen Submits Application Seeking FDA Approval Of Stelara For The Treatment Of Pediatric Patients With Juvenile Psoriatic Arthritis

Published: 10/08/2021 12:20 GMT
Johnson & Johnson (JNJ) - Janssen Submits Application Seeking FDA Approval of Stelara (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis.
Janssen- Submission of Sbla to FDA Seeking Expanded Approval of Stelara to Treat Pediatric Patients Age 5 Yrs, Older With Juvenile Psoriatic Arthritis.